Mangoceuticals (MGRX) Return on Sales (2023 - 2026)

Mangoceuticals (MGRX) has 4 years of Return on Sales data on file, last reported at 0.5% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales fell 6.0% year-over-year to 0.5%; the trailing twelve-month figure through Mar 2026 stood at 0.46% (down 24.0% YoY), and the FY2025 full-year result was 0.36%, down 25.0% from the prior year.
• Return on Sales declined to 0.5% in Q1 2026, from 0.29% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.07% in Q3 2023 to a low of 0.9% in Q3 2025.
• A 4-year average of 0.28% and a median of 0.19% in 2024 frame the typical range for Return on Sales.
• Across the five-year window, Return on Sales climbed 14 bps in 2024 and slumped 75 bps in 2025, its largest moves.
• Tracing MGRX's Return on Sales over 4 years: stood at 0.11% in 2023, then tumbled by 76 bps to 0.19% in 2024, then slumped by 59 bps to 0.29% in 2025, then plunged by 71 bps to 0.5% in 2026.
• Business Quant data shows MGRX's Return on Sales at 0.5% in Q1 2026, 0.29% in Q4 2025, and 0.9% in Q3 2025.